Special Issue

Human Leukocyte Antigen (HLA)—Antigen Interactions in Vaccine Development

Message from the Guest Editor

Vaccines are used to prevent illnesses caused by pathogens. Vaccines contain antigens of pathogens that induce the host to produce antibodies against them. The success of vaccines in prevention or therapy depends on the ability of the host to make antibodies against the vaccine antigen(s). In turn, this depends on host immunogenetics, i.e., the availability of human leukocyte antigen (HLA) alleles that can form a complex with the antigen (or its fragments) to engage CD4+ T lymphocytes and then B cells for antibody formation. Thus, this antigen–HLA interaction is critical for the production of antibodies and success of the vaccine. This Special Issue centers on this association between vaccine antigens and HLA molecules that initiate antibody production. This journal welcomes original research articles and reviews on research areas focusing on antigen–HLA interactions in vaccine development and vaccine effectiveness. Research or review articles on the role of HLA in antigen presentation, antibody production, and vaccine effectiveness are welcome.

Guest Editor

Prof. Dr. Apostolos P. Georgopoulos
Department of Neuroscience, Brain Sciences Center, University of Minnesota Medical School, Minneapolis, MN 55455, USA

Deadline for manuscript submissions

31 July 2026

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/197119

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

MDPI